Achieve Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference

Rhea-AI Summary

Achieve Life Sciences (NASDAQ:ACHV) will have CEO John Bencich present at the H.C. Wainwright BioConnect Conference from January 11-14, 2021. The presentation will be available via webcast starting January 11 at 6:00 AM EST on the Achieve Investor Relations page. The company focuses on developing cytisinicline, a plant-based treatment for nicotine addiction, which is approved in Central and Eastern Europe and has helped over 20 million users. Smoking remains a leading cause of preventable death worldwide, emphasizing the importance of Achieve’s mission.

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that John Bencich, Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference being held virtually January 11-14, 2021.

A webcast of the presentation will be available on Monday, January 11^th at 6:00 AM EST and can be accessed by visiting the Achieve Investor Relations page http://ir.achievelifesciences.com/events-and-webcasts.

About Achieve and Cytisinicline
Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the U.S. annually.^1,2 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.²

Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in smoking cessation by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms and by reducing the reward and satisfaction associated with smoking.

As an approved, branded product in Central and Eastern Europe for more than two decades, it is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction.

Investor Relations Contact
Jason Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4

References

¹ World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.

² U.S. Department of Health and Human Services. The Health Consequences of Smoking - 50 Years of Progress. A Report of the Surgeon General, 2014.

SOURCE: Achieve Life Sciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/623186/Achieve-Life-Sciences-to-Present-at-HC-Wainwright-Virtual-BioConnect-Conference

FAQ

When is Achieve Life Sciences presenting at the H.C. Wainwright BioConnect Conference?

Achieve Life Sciences will present at the H.C. Wainwright BioConnect Conference from January 11-14, 2021.

What is cytisinicline and how does it help with smoking cessation?

Cytisinicline is a plant-based alkaloid that helps reduce nicotine withdrawal symptoms and the satisfaction of smoking, aiding in smoking cessation.

How long has cytisinicline been available as a treatment for nicotine addiction?

Cytisinicline has been an approved treatment in Central and Eastern Europe for more than two decades.

How many people have used cytisinicline for nicotine addiction?

It is estimated that over 20 million people have used cytisinicline to combat nicotine addiction.

What are the key health risks associated with smoking?

Smoking leads to more than eight million deaths globally each year and is linked to lung cancer, pulmonary diseases, and heart disease.